Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

• Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)
• Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)
• Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)
• Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)
• Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34)
• Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16)
• Case: Patient with ER-positive, HER2-negative breast cancer receives camizestrant after first-line tamoxifen (36:20)
• Case: Patient with ER-positive, HER2-negative breast cancer receives elacestrant after disease progression on first-line letrozole/palbociclib (38:11)

CME information and select publications

Featuring an interview from Dr John Strickler, including the following topics:

• Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00)
• Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09)
• Tumor-informed MRD assays under clinical development (20:36)
• Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19)
• Case: A man in his late 50s with resected Stage IIA colon cancer (30:06)
• Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57)
• MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24)
• Antibody-drug conjugates in the treatment of colorectal cancer (45:13)
• Perspectives on promising areas of clinical research in colorectal cancer (48:23)

CME information and select publications

Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics:

• Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00)
• GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased risk of recurrence and those who are likely to benefit from adjuvant chemotherapy (6:56)
• Sustained circulating tumor DNA (ctDNA) clearance and disease-free survival outcomes for patients with localized colorectal cancer (13:21)
• DYNAMIC study of a ctDNA-guided approach to adjuvant chemotherapy for patients with Stage II colorectal cancer (16:17)
• ctDNA positivity and radiographic evidence of colorectal cancer (18:48)
• ctDNA-guided approaches to escalating or de-escalating adjuvant chemotherapy for patients with localized colorectal cancer (21:24)
• Predictive role of ctDNA assay results in Stage III colon cancer treated with celecoxib; low-dose aspirin for patients with Stage II to III colorectal cancer with a PI3K pathway alteration (26:02)

CME information and select publications